Sandra Tong

553 total citations
18 papers, 394 citations indexed

About

Sandra Tong is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Sandra Tong has authored 18 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Sandra Tong's work include Chronic Lymphocytic Leukemia Research (8 papers), Platelet Disorders and Treatments (8 papers) and Blood groups and transfusion (4 papers). Sandra Tong is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Platelet Disorders and Treatments (8 papers) and Blood groups and transfusion (4 papers). Sandra Tong collaborates with scholars based in United States, United Kingdom and Canada. Sandra Tong's co-authors include Michael Boxer, Nichola Cooper, James B. Bussel, Donald M. Arnold, Ernest Brahn, Anne‐Marie Duliège, Mark C. Genovese, Daniel G. Baker, Michael E. Weinblatt and Gary S. Firestein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Human Molecular Genetics.

In The Last Decade

Sandra Tong

18 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Tong United States 9 177 87 87 79 74 18 394
Shinya Rai Japan 11 106 0.6× 128 1.5× 150 1.7× 162 2.1× 71 1.0× 47 385
Adrian Tempescul France 12 89 0.5× 125 1.4× 121 1.4× 133 1.7× 110 1.5× 46 408
Ruirong Yuan United States 9 76 0.4× 209 2.4× 75 0.9× 54 0.7× 204 2.8× 11 470
Gabriella Benetton Italy 8 205 1.2× 207 2.4× 37 0.4× 88 1.1× 92 1.2× 13 592
A. Lyndsay Drayer Netherlands 14 212 1.2× 150 1.7× 18 0.2× 62 0.8× 135 1.8× 17 451
Steve De Vos Belgium 7 46 0.3× 98 1.1× 24 0.3× 72 0.9× 135 1.8× 11 354
Federica Toffalini Belgium 6 67 0.4× 207 2.4× 25 0.3× 46 0.6× 63 0.9× 10 363
Carl Högberg Sweden 12 184 1.0× 159 1.8× 20 0.2× 43 0.5× 87 1.2× 18 466
Celina Montemayor United States 13 87 0.5× 236 2.7× 25 0.3× 65 0.8× 134 1.8× 27 558

Countries citing papers authored by Sandra Tong

Since Specialization
Citations

This map shows the geographic impact of Sandra Tong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Tong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Tong more than expected).

Fields of papers citing papers by Sandra Tong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Tong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Tong. The network helps show where Sandra Tong may publish in the future.

Co-authorship network of co-authors of Sandra Tong

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Tong. A scholar is included among the top collaborators of Sandra Tong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Tong. Sandra Tong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Tong, Sandra, Pamela Ventola, Jennifer M. Phillips, et al.. (2023). NGLY1 deficiency: a prospective natural history study. Human Molecular Genetics. 32(18). 2787–2796. 6 indexed citations
2.
Dwight, Selina S., et al.. (2022). NGLY1 deficiency: estimated incidence, clinical features, and genotypic spectrum from the NGLY1 Registry. Orphanet Journal of Rare Diseases. 17(1). 440–440. 13 indexed citations
3.
Kuter, David J., Kerry A. Rogers, Michael Boxer, et al.. (2022). Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study. American Journal of Hematology. 97(6). 691–699. 26 indexed citations
4.
Mallat, Ziad, Suzana Margareth Lobo, Anuj Malik, & Sandra Tong. (2021). 561. Phase 3 Trial of Fostamatinib for the Treatment of COVID-19: Repurposing an Immunomodulatory Drug Previously Approved for Immune Thrombocytopenia. Open Forum Infectious Diseases. 8(Supplement_1). S382–S383. 3 indexed citations
5.
6.
Boccia, Ralph V., Nichola Cooper, Waleed Ghanima, et al.. (2020). Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia. British Journal of Haematology. 190(6). 933–938. 46 indexed citations
7.
Dummer, Wolfgang, Vadim Markovtsov, Sandra Tong, & Esteban S. Masuda. (2020). Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications. Blood. 136(Supplement 1). 35–35. 2 indexed citations
8.
Cooper, Nichola, Robert P. Numerof, Sandra Tong, & David J. Kuter. (2020). Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. Blood. 136(Supplement 1). 1–3. 4 indexed citations
9.
Arkenau, Hendrik‐Tobias, et al.. (2020). Fostamatinib for the treatment of diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 38(15_suppl). e20067–e20067. 3 indexed citations
10.
Tumlin, James A., Jonathan Barratt, Candice Roufosse, et al.. (2019). SUN-036 SPLEEN TYROSINE KINASE (SYK) INHIBITION IN IGA NEPHROPATHY: A GLOBAL, PHASE II, RANDOMISED PLACEBO-CONTROLLED TRIAL OF FOSTAMATINIB. Kidney International Reports. 4(7). S168–S168. 15 indexed citations
11.
Bussel, James B., Donald M. Arnold, Michael Boxer, et al.. (2019). Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. American Journal of Hematology. 94(5). 546–553. 81 indexed citations
12.
Duliège, Anne‐Marie, Donald M. Arnold, Ralph V. Boccia, et al.. (2018). Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program. Blood. 132(Supplement 1). 736–736. 8 indexed citations
13.
Jankú, Filip, Ulka N. Vaishampayan, Vivek Khemka, et al.. (2018). Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors. Molecular Cancer Therapeutics. 17(1_Supplement). B176–B176. 3 indexed citations
14.
15.
Patnaik, Amita, Peter D. Eisenberg, Jasgit C. Sachdev, et al.. (2016). Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS11618–TPS11618. 2 indexed citations
16.
Wainberg, Zev A., Peter D. Eisenberg, Jasgit C. Sachdev, et al.. (2016). Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.. Journal of Clinical Oncology. 34(4_suppl). TPS465–TPS465. 17 indexed citations
17.
Tong, Sandra, Stephen E. Daniels, Peter M. Black, et al.. (2011). Novel p38α Mitogen‐Activated Protein Kinase Inhibitor Shows Analgesic Efficacy in Acute Postsurgical Dental Pain. The Journal of Clinical Pharmacology. 52(5). 717–728. 32 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinya Rai Breakdown of academic impact, for papers by Adrian Tempescul Breakdown of academic impact, for papers by Ruirong Yuan Breakdown of academic impact, for papers by Gabriella Benetton Breakdown of academic impact, for papers by A. Lyndsay Drayer Breakdown of academic impact, for papers by Steve De Vos Breakdown of academic impact, for papers by Federica Toffalini Breakdown of academic impact, for papers by Carl Högberg Breakdown of academic impact, for papers by Celina Montemayor
Rankless by CCL
2026